Retrieve available abstracts of 41 articles: HTML format
Single Articles
March 2025
BHAMANI A, Creamer A, Verghese P, Prendecki R, et al Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a
prospective, longitudinal cohort study.
Lancet Oncol. 2025 Mar 25:S1470-2045(25)00082. PubMedAbstract available
HEUVELMANS MA Lung cancer screening implementation: turning evidence into practice.
Lancet Oncol. 2025 Mar 25:S1470-2045(25)00138. PubMed
GOURD E Lung cancer treatment compromised by delayed genomic test results.
Lancet Oncol. 2025 Mar 13:S1470-2045(25)00149. PubMed
February 2025
LI Z, Wang Y, Sun Y, Wang L, et al Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with
advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results
from a multicentre, single-arm study.
Lancet Oncol. 2025 Feb 25:S1470-2045(25)00012. PubMedAbstract available
January 2025
SEN T, Dotsu Y, Corbett V, Puri S, et al Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic
challenges, and diagnosis and management strategies.
Lancet Oncol. 2025;26:e13-e33. PubMedAbstract available
XU Y, Chen K, Xu Y, Li H, et al Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy
for previously untreated advanced non-small-cell lung cancer with brain
metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2025;26:74-84. PubMedAbstract available
December 2024
ZHAO Y, Xiong S, Ren Q, Wang J, et al Deep learning using histological images for gene mutation prediction in lung
cancer: a multicentre retrospective study.
Lancet Oncol. 2024 Dec 6:S1470-2045(24)00599. PubMedAbstract available
November 2024
GOURD E Lung cancer rates highest among British Bangladeshi men.
Lancet Oncol. 2024 Nov 28:S1470-2045(24)00683. PubMed
HEINZERLING JH, Mileham KF, Robinson MM, Symanowski JT, et al Primary lung tumour stereotactic body radiotherapy followed by concurrent
mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced
non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2024 Nov 27:S1470-2045(24)00573. PubMedAbstract available
FURLOW B American Lung Association calls for expanded insurance coverage for lung cancer
screening.
Lancet Oncol. 2024 Nov 21:S1470-2045(24)00670. PubMed
THUREAU S, Giraud P, Zalcman G, Vera P, et al [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer -
Authors' reply.
Lancet Oncol. 2024;25:e541. PubMed
BOWEN JONES S, Cooke S, Belderbos J, Faivre-Finn C, et al [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
Lancet Oncol. 2024;25:e540. PubMed
XU X, Ye L, Shi J, Li H, et al [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
Lancet Oncol. 2024;25:e539. PubMed
October 2024
PROVENCIO M, Nadal E, Insa A, Garcia Campelo R, et al Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM):
5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2024 Oct 14:S1470-2045(24)00498. PubMedAbstract available
WOLF J, Hochmair M, Han JY, Reguart N, et al Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from
the open-label, phase 2 GEOMETRY mono-1 trial.
Lancet Oncol. 2024;25:1357-1370. PubMedAbstract available
August 2024
GOURD E World's first lung cancer vaccine trial launched in the UK.
Lancet Oncol. 2024 Aug 30:S1470-2045(24)00324. PubMed
ZHAO Y, He Y, Wang W, Cai Q, et al Efficacy and safety of immune checkpoint inhibitors for individuals with advanced
EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase
inhibitors: a systematic review, meta-analysis, and network meta-analysis.
Lancet Oncol. 2024 Aug 16:S1470-2045(24)00379. PubMedAbstract available
VERA P, Thureau S, Le Tinier F, Chaumet-Riffaud P, et al Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients
with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour
residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled
phase 2 t
Lancet Oncol. 2024 Aug 9:S1470-2045(24)00320. PubMedAbstract available
WU YL, Guarneri V, Voon PJ, Lim BK, et al Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung
cancer with MET amplification following progression on first-line osimertinib
(INSIGHT 2): a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2024;25:989-1002. PubMedAbstract available
TENDLER S, Dunphy MP, Agee M, O'Donoghue J, et al Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with
high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2,
first-in-human trial.
Lancet Oncol. 2024;25:1015-1024. PubMedAbstract available
July 2024
LAZARATOS AM, Petrecca K, Guiot MC, Jerzak KJ, et al CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung
cancer.
Lancet Oncol. 2024;25:e282. PubMed
AERTS JG, Belderbos R, Baas P, Scherpereel A, et al Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive
care versus best supportive care alone in patients with pleural mesothelioma as
maintenance therapy after chemotherapy (DENIM): a multicentre, open-label,
randomised, phase
Lancet Oncol. 2024;25:865-878. PubMedAbstract available
ZAUDERER MG, Dagogo-Jack I Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM
trial.
Lancet Oncol. 2024;25:825-827. PubMed
June 2024
CHEN L, Zhu XZ, Zhao SJ, Yang QW, et al PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
Lancet Oncol. 2024;25:e233. PubMed
May 2024
BURKI T EPA ruling to ban chrysotile asbestos.
Lancet Oncol. 2024;25:537. PubMed
April 2024
SMIT EF, Felip E, Uprety D, Nagasaka M, et al Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer
(DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a
single-arm, phase 2 trial.
Lancet Oncol. 2024;25:439-454. PubMedAbstract available
March 2024
GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al Correlations of response rate and progression-free survival with overall survival
in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled
analysis.
Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040. PubMedAbstract available
February 2024
RHA SY, Bordia S Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.
Lancet Oncol. 2024;25:e52. PubMed
SCHUTTE T, Derks S, van Laarhoven HWM Pembrolizumab plus chemotherapy for advanced gastric cancer.
Lancet Oncol. 2024;25:e51. PubMed
HUANG CY, Wu XB Pembrolizumab plus chemotherapy for advanced gastric cancer.
Lancet Oncol. 2024;25:e50. PubMed
January 2024
RASHID T, Bennett JE, Muller DC, Cross AJ, et al Mortality from leading cancers in districts of England from 2002 to 2019: a
population-based, spatiotemporal study.
Lancet Oncol. 2024;25:86-98. PubMedAbstract available
December 2023
LEAL T, Langer C Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors'
reply.
Lancet Oncol. 2023;24:e454. PubMed
OLIVIER T, Addeo A Tumor Treating Fields therapy in metastatic non-small-cell lung cancer.
Lancet Oncol. 2023;24:e453. PubMed
FURLOW B IASLC calls for clinical trials to use tobacco use data.
Lancet Oncol. 2023;24:1309. PubMed
November 2023
SCOTT SE, Gildea C, Nicholson BD, Evans RE, et al Future cancer risk after urgent suspected cancer referral in England when cancer
is not found: a national cohort study.
Lancet Oncol. 2023;24:1242-1251. PubMedAbstract available
DOUMA LH, Lalezari F, van der Noort V, de Vries JF, et al Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural
mesothelioma (PEMMELA): a single-arm phase 2 study.
Lancet Oncol. 2023;24:1219-1228. PubMedAbstract available
October 2023
COOPER WA Lessons and opportunities from improved understanding of global lung cancer
histological subtypes.
Lancet Oncol. 2023 Oct 11:S1470-2045(23)00475. PubMed
ZHANG Y, Vaccarella S, Morgan E, Li M, et al Global variations in lung cancer incidence by histological subtype in 2020: a
population-based study.
Lancet Oncol. 2023 Oct 11:S1470-2045(23)00444. PubMedAbstract available
HU X, Wang C, Huang W, Barber SM, et al Pembrolizumab monotherapy for advanced chordoma.
Lancet Oncol. 2023;24:e399. PubMed
September 2023
FENNELL DA Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell
lung cancer.
Lancet Oncol. 2023;24:946-947. PubMed
LEAL T, Kotecha R, Ramlau R, Zhang L, et al Tumor Treating Fields therapy with standard systemic therapy versus standard
systemic therapy alone in metastatic non-small-cell lung cancer following
progression on or after platinum-based therapy (LUNAR): a randomised, open-label,
pivotal phase 3 st
Lancet Oncol. 2023;24:1002-1017. PubMedAbstract available